Dr. Reddy's Laboratories Ltd stock (INE089A01023): shares under pressure after weak EPS trend highlighted

Dr. Reddy's Laboratories Ltd shares on the National Stock Exchange of India came under renewed scrutiny on 06/02/2026 as local media highlighted a sharp year-on-year decline in March-quarter EPS and a negative one-month return, keeping the Nifty 50 constituent in focus.

Dr. Reddy's Laboratories Ltd, a major pharmaceutical name in India and a constituent of the Nifty 50 index, was back in the spotlight on 06/02/2026 as domestic market coverage pointed to a weak recent return profile and a sharp decline in earnings per share for the March 2026 quarter, keeping pressure on the stock in Mumbai trading, according to The Economic Times as of 06/02/2026.

The Economic Times noted that the stock registered a monthly return of approximately -2.5% over the past month as of 06/02/2026, underperforming broader Indian benchmarks and adding to a stretch of softer trading for the Hyderabad-headquartered company in its home market on the National Stock Exchange of India under the ticker DRREDDY, as reported by The Economic Times as of 06/02/2026.

The company remains actively traded in India, with the National Stock Exchange quoting the shares in Indian rupees and carrying the latest corporate disclosures, including financial results and governance updates, according to NSE India as of 06/02/2026.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Dr Reddy
• Sector/industry: Pharmaceuticals and generics
• Headquarters/country: Hyderabad, India
• Core markets: India, North America, Europe and emerging markets
• Key revenue drivers: Generic formulations, active pharmaceutical ingredients and branded prescription products
• Home exchange/listing venue: National Stock Exchange of India (DRREDDY) and BSE
• Trading currency: INR

Dr. Reddy's Laboratories Ltd: core business model

Dr. Reddy's Laboratories Ltd focuses on developing, manufacturing and marketing generic and specialty pharmaceutical products across global markets, with revenue primarily generated from prescription formulations and ingredients supplied to healthcare systems in India and overseas.

Latest quarterly results for Dr. Reddy's Laboratories Ltd at a glance

Indian financial press recently underscored that Dr. Reddy's reported an earnings per share figure of INR 2.65 for the March 2026 quarter, markedly below the INR 19.10 EPS reported in the same quarter a year earlier, highlighting a pronounced year-on-year decline in per-share profitability, according to a slideshow overview from The Economic Times as of 06/01/2026.

The same Economic Times summary placed Dr. Reddy's among a group of seven Indian stocks that have shown declining EPS for four consecutive quarters as of the March 2026 reporting period, signaling sustained earnings pressure that investors in the Mumbai-listed shares are monitoring closely, according to The Economic Times as of 06/01/2026.

Conclusion

The focus on Dr. Reddy's Laboratories Ltd in Indian trading on 06/02/2026 reflects both the recent negative monthly return profile and the backdrop of four quarters of declining EPS, culminating in a March 2026 per-share result of INR 2.65 versus INR 19.10 a year earlier. For investors tracking the Nifty 50 member, the latest numbers highlighted by domestic media serve as a reminder that earnings trends remain a key driver of sentiment alongside the broader performance of Indian pharmaceutical stocks.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.